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Introduction
Unraveling the fundamental mechanisms and pathways
behind protein misfolding and aggregation is one of the great
challenges of current science. The failure of specific proteins to
fold correctly or to remain correctly folded and their subse-
quent self-assembly into dysfunctional or indeed toxic aggre-
gates is associated with a range of highly debilitating and
increasingly prevalent pathological conditions.[1] These include
neurodegenerative disorders, such as Alzheimer’s (AD) and Par-
kinson’s (PD) diseases, in which the peptide fragment amyloid-
b (Ab) and the proteins tau and a-synuclein form insoluble
and highly ordered linear aggregates, known as amyloid fibrils.
It is a challenge to study in real time the formation of the dif-
ferent molecular species on the pathway from monomeric to
highly ordered fibrillar structures, but these studies are essen-
tial in order to explore the relationship between aggregate
structure, toxic properties, and clinical symptoms further. In
addition, robust assays of aggregation are vital in the search
for, and investigation of, aggregation-inhibiting compounds
that selectively interfere with individual molecular steps along
the overall conversion pathway.
Although the morphology, size, and biological function of
parent polypeptides are remarkably diverse, all amyloid fibrils
share common structural properties. They consist of highly
ordered b-strands that lie perpendicular to a common axis in
a so-called cross-b arrangement.[2] The peptides are intercon-
nected by an extensive network of hydrogen bonds aligned in
parallel with the fibril axis. The hydrogen bond network stabil-
izes the amyloid fibrils and is thought to be the origin of their
remarkable properties, such as high thermodynamic[3] and me-
chanical[4] stability. Recently, it has been found that amyloid-
like structure is associated with an intrinsic fluorescent phe-
nomenon that occurs in the visible range.[5–8]
In this paper, we show that this phenomenon can be used
to track the aggregation of amyloid proteins noninvasively and
quantitatively without any need for extrinsic labels. We validate
the method against an established assay of protein aggrega-
tion and compare the increase in the intrinsic fluorescence
emission intensity with the change in Thioflavin T (ThT) fluores-
cent signal under conditions that give highly reproducible
fibril-growth kinetics. We quantify the conversion from the
soluble into aggregated forms of two proteins in real time and
use atomic force microscopy (AFM) and confocal imaging to
probe the identity of the species giving rise to the observed
fluorescence signatures. We also show that the assay is com-
patible with standard confocal microscope setups, so that
both spatial (structural) and spectral information can be moni-
tored simultaneously from fibril assemblies. The intrinsic fluo-
rescence assay has an excellent dynamic range, similar to that
of ThT fluorescence, but with the significant advantage that no
extrinsic labels are required, neither is the presence of aromatic
residues necessary;[9, 10] thus it can be applied to a wider range
of amyloid proteins. Furthermore, we show that this assay per-
mits us to study the interaction of small-molecule compounds
with aggregates in situations in which the ThT assay fails.
Using the effect of lacmoid on the aggregation of a-synuclein
as an example, we show that the intrinsic fluorescence assay
faithfully reports on amyloid growth, in contrast to ThT fluores-
cence, which is strongly affected by the presence of lacmoid.
Results and Discussion
Amyloid fibrils from different polypeptide sequences exhibit
similar fluorescence properties in the visible range
We have performed detailed spectroscopic measurements on
a series of amyloid fibrils, and all exhibited an intrinsic fluores-
cence, thus suggesting that this is a generic feature of the
amyloid form of proteins. We used a purpose-built confocal
microscope, equipped with spectral emission imaging and life-
time measurement capability,[11–13] to allow us to probe the
fibril-assembly process directly and to measure the fluores-
cence properties of the aggregates, thereby showing that the
emission originates from fibrillar species. The underlying mor-
phology of the aggregates was also measured at higher resolu-
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tion by AFM. Figure 1 shows an analysis of aggregates of the
amyloid-b peptide (1–42) (Ab42), the 129-residue tau protein
isoform K18 (I260C/C291A/C322A variant) and the 140-residue
and natively unfolded protein a-synuclein, which are associat-
ed with AD (Ab42 and tau) and PD (a-synuclein). Figure 1A
shows high-resolution AFM images of the fibril morphologies
that reveal fibrillar structures for all three species, but also
clear morphological differences between observed aggregates.
Figure 1B shows the corresponding confocal fluorescence life-
time images of the same structures at a lower inherent resolu-
tion, but also reveals the presence of individual aggregate clus-
ters. The color scale in Figure 1B reflects the fluorescence life-
times of individual fibrils that were obtained by time-correlated
single photon counting (TCSPC; see the Experimental Section).
The lifetimes are in the 1 to 3 ns range, orders of magnitude
larger than the excitation pulse length (ca. 10 ps). The corre-
sponding fluorescence spectra are shown in Figure 1C. Clearly
the fluorescence is Stokes shifted from the excitation wave-
length (405 nm), with a peak centered at ~460 nm and similar
for all three species. The corresponding proteins in their mono-
meric form do not display any fluorescence signal, as is shown
by the red traces in the insets. Fibrils could also be photo-
bleached over extended periods of irradiation and furthermore
exhibit two-photon excitation spectra similar to their one-
photon counterparts shown here; the spectral properties are
identical for solid-phase synthesized or recombinantly ex-
pressed amino acid sequences (see the Supporting Informa-
tion). The similarities in the lifetime and spectral signatures be-
tween the three species are remarkable, given their differences
in amino acid sequence and aggregate morphology. These
findings substantiate the hypothesis made previously, that the
intrinsic fluorescence phenomenon is a generic property of the
cross b-sheet arrangement in amyloid fibrils,[5, 7] and is likely
related to the extensive arrangement of hydrogen-bond net-
works running along the fibril axis.[6] Crucially, we also show
that intrinsic fluorescence permits individual fibrils to be
imaged microscopically without any use of extrinsic labels.
Figure 1. Intrinsic fluorescence in the visible range detected from three different amyloid fibrils formed in vitro. A) AFM images of fibrils formed from
i) human tau K18, ii) human Ab42 fibrils, and iii) human a-synuclein fibrils. B) Intrinsic fluorescence lifetime images of the same amyloid fibrils obtained by con-
focal microscopy. C) Black traces: emission spectra of the intrinsic fluorescence from specific aggregates as indicated in (B). Red traces: fluorescence signal
from the corresponding monomeric protein (shown rescaled in the insets). The laser excitation wavelength was 405 nm.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2013, 14, 846 – 850 847
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Protein aggregation reactions can be spectroscopically
monitored without the need for extrinsic labels
A key problem in the validation of a new assay of amyloid
growth is the difficulty of obtaining standardized and calibrat-
ed aggregation conditions because the observed growth kinet-
ics are the result of a complex interplay of underlying elemen-
tary reaction steps. Amyloid fibrils form through a nucleated
growth process,[14] during which monomeric peptide slowly as-
sociates to form an oligomeric nucleus. This primary nucleation
process is followed by an elongation phase in which the nu-
cleus grows, typically by sequential incorporation of monomer-
ic protein molecules, to form protofilaments and eventually
mature fibrils. In addition, secondary pathways have been
shown to play a significant role in the overall conversion of
soluble peptide into aggregates.[15,16] Such secondary processes
include the fragmentation of fibrils[15] and monomer-depen-
dent secondary nucleation, in which the fibrils themselves act
to stimulate nucleation on their surfaces.[17] In the presence of
preformed “seed” fibrils, the aggregation reaction can be con-
siderably accelerated, and when the system is sufficiently heav-
ily seeded, the only relevant molecular process is elongation,
and thus the reaction follows exponential growth kinetics.[18]
The resulting reduction in complexity of the aggregation path-
way and the lack of dependence on stochastic primary nuclea-
tion reactions greatly improve the reproducibility of aggrega-
tion experiments and this is exploited in our work.
In particular, we studied the seeded growth of amyloid fibrils
of a-synuclein by using both the label-free intrinsic fluores-
cence and the ThT assays. The starting point was a sample con-
taining preformed amyloid fibrils of the protein after sonica-
tion of preaggregated species to yield short seed fibrils (Fig-
ure 2A; see the Supporting Information). Protein monomer
was added to this sample at a tenfold excess with respect to fi-
brils ; the sample was then incubated at 37 8C for 5 h during
which the intrinsic fluorescence intensity was recorded with
a confocal microscope. The laser excitation wavelength was
405 nm, and the detection range was set to cover the 430 to
530 nm spectral range. Figure 2C illustrates the fluorescence
intensity increase during aggregation, and Figure 2B shows
AFM images that confirm the elongation of the fibrils. In the
presence of a sufficient concentration of seed fibrils, the pro-
tein aggregation kinetics do not involve a lag phase and
follow simple exponential behavior[18] due to monomer deple-
tion. The observed increase in intrinsic fluorescence originates
from the addition of soluble protein to the ends of seed aggre-
gates, as depicted in the schematic of Figure 2A, and this
leads to an overall increase of aggregate mass and length. The
acquired data are well described by a single exponential func-
tion of the form y=y0+A1 exp((t/t1)) (red line in Figure 2C).
As a control, we also incubated seed fibrils of a-synuclein with
monomeric b-synuclein. The sequence of b-synuclein is related
to that of a-synuclein, but the b form does not aggregate
under the conditions used here[19] and is known not to be in-
corporated into a-synuclein fibrils.[20] As expected, the increase
in intrinsic fluorescence is insignificant over a time period of
several hours (Figure 2C, black curve). Furthermore, in an addi-
tional experiment (see the Supporting Information), we dem-
onstrated that the intrinsic fluorescence tracks fibril growth in
a linear, dose-dependent way.
We also tested the capability of the assay to capture the full
time course of aggregation in the absence of seed fibrils. We
incubated a sample containing K18 tau monomers at 37 8C
with heparin (see the Experimental Section) and recorded the
time evolution of the intrinsic fluorescence intensity over sev-
eral hours (Figure 3). The curve exhibits an initial lag phase
Figure 2. Kinetic assay of the seeded growth of a-synuclein. A) Simple sche-
matic diagram illustrating the seeding process. Blue rods denote a-synuclein
seeds, and red rods denote monomeric protein; ke=elongation rate con-
stant. B) AFM images of sonicated seed fibrils and of the a-synuclein fibrils
formed at the end of the reaction in the experiment shown in (C). C) Blue
trace: Kinetic trace of the change in intrinsic fluorescence intensity over 5 h
during seeded aggregation of a-synuclein. Seeds (7 mm) were incubated at
37 8C with a-synuclein monomeric protein (70 mm). Black trace: intrinsic fluo-
rescence intensity over 5 h for a-synuclein seeds (7 mm) incubated with b-
synuclein monomeric protein (70 mm) ; here no increase in the intrinsic fluo-
rescence is observed, and hence no seeded growth. Red curve: exponential
fit to the data.
Figure 3. Nucleation and growth of tau K18 amyloid aggregates monitored
by intrinsic fluorescence (blue dots). Red curve: sigmoidal fit to these points.
Unlabeled human K18 tau monomers formed fibrils in vitro and were
imaged on a confocal fluorescence microscope by using laser excitation at
405 nm. At t=0 heparin was added, and the ensuing aggregation reaction
was observed for 4 h.
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until around t=1 h, after which a steep rise in signal is
observed; this corresponds to the growth of fibrils. The rate
slows down as the monomer is consumed in the conversion to
amyloid fibrils ; this yields overall the typical sigmoidal profile
of a time course of amyloid formation.[16]
Small molecules can cause interference with ThT fluores-
cence but do not affect the intrinsic amyloid fluorescence
A detailed understanding of the protein aggregation reaction
is crucial in order to explore new therapeutic strategies by
rational means so as to find therapies against a range of debili-
tating human disorders. Traditional assays require extrinsic
labels such as ThT,[21,22] Congo Red (CR),[23] and 1-anilino-8-
naphthalene sulfonate (ANS) dyes.[24] These systems are of
great value, but in the search for small molecules labels can in-
fluence the kinetics and mechanisms of the aggregation pro-
cess, as they can interfere with the binding of the inhibitor
molecule or the inhibitor molecule can quench the fluores-
cence of the label.[25–27] We therefore tested the ability of our
label-free intrinsic fluorescence assay to quantify amyloid
growth in a situation in which experiments with ThT fluores-
cence are known to be challenging. Lacmoid is a small mole-
cule that binds to amyloidogenic proteins and was previously
thought to act as a potential inhibitor of aggregation. We
therefore studied the aggregation of a-synuclein in the pres-
ence and absence of 100 mm lacmoid (Figure 4) and monitored
the aggregation by using ThT and the intrinsic fluorescence
assay. The intrinsic fluorescence is seen to rise in an almost
identical fashion whether lacmoid is present (red points) or
absent (blue points), and in agreement with earlier reports,[25]
we thus verify that, at the stated concentration and in the
presence of seed fibrils, lacmoid causes no inhibition of a-syn-
uclein aggregation. The ThT fluorescence traces, however, vary
significantly according to the presence (red line) or absence
(blue line) of lacmoid. The observed dramatic decrease in fluo-
rescence intensity (ca. fivefold) could be mistaken for an inhibi-
tory action of lacmoid but is likely to be caused either by
a quenching interaction between ThT and lacmoid, or by com-
petition between ThT and lacmoid for free binding sites on the
amyloid fibrils.
Conclusions
In conclusion, we have demonstrated and characterized an all-
optical kinetic assay of protein aggregation that is label-free
and reproducible, and which can be used to study the kinetics
of amyloid formation in real time. The assay is based on the in-
trinsic fluorescence associated with the amyloid form of poly-
peptides, an intriguing biophysical phenomenon that has re-
cently been discovered and is stimulating much further bio-
physical investigation. The method eliminates the need for ex-
trinsic labeling and thus excludes the risk of steric interactions
and other perturbations during aggregation. Although the in-
trinsic fluorescence intensity is weaker than that of extrinsic
fluorophores, our assay is simple to use (requiring only a confo-
cal microscope), offers a similar dynamic range to traditional
assays such as ThT, and reports quantitatively and reproducibly
on amyloid fibrillar growth. We have demonstrated the poten-
tial of studying the interactions of small-molecule binding to
amyloid fibrils through intrinsic fluorescence and shown that
this method is more reliable than assays requiring extrinsic dye
labels. Given its well-defined nature and straightforward appli-
cation, we anticipate the widespread use of this method in the
study of protein aggregation and in the search for small mole-
cules that are potential therapeutic lead compounds.
Experimental Section
Materials: All chemicals for the preparation of buffers, as well as
the heparin and the lacmoid were purchased from Sigma–Aldrich.
The “synthetic” human Ab(1–42) (Bachem, Merseyside, UK) was
prepared by sequential treatment with trifluoroacetic acid (TFA)
and hexafluoroisopropanol (HFIP) to remove small aggregates and
stored as a lyophilized film in Eppendorf tubes at 20 8C.[28] Sam-
ples were freshly thawed just before each set of experiments. Re-
combinant human Ab(1–42) was expressed and purified as de-
scribed previously,[29] except for the size-exclusion chromatography
(SEC) step. The peptide was carefully divided into aliquots after the
anion-exchange step. The tau construct K18 (I260C/C291A/C322A)
was prepared as described in ref. [30]. Human a-synuclein was
expressed and purified as described in ref. [31].
Conversion of soluble polypeptides into fibrils: Lyophilized, TFA-
and HFIP-treated human Ab(1–42) were dissolved in 1PBS buffer
(pH 7.4) at 50 mm peptide concentration in Eppendorf tube, and
the solutions were incubated at 37 8C for 7 days. A lyophilized
(from 1.5 mL, 10 mm Tris, pH 8.5, 125 mm NaCl, 1 mm EDTA) aliquot
(15 nmol) of recombinant Ab(1–42) was dissolved in deionized
water (150 mL) and left to aggregate at room temperature over-
night. K18 (I260C/C291A/C322A) tau (10 mm in 50 mm ammonium
acetate buffer, pH 7.2) was incubated at 37 8C for 24 h, quiescent,
in the presence of heparin (2.5 mm, MW3000, Sigma–Aldrich). All
buffers were made with Milli-Q water and were filtered with
0.20 mm filters (Millipore) before use. Human a-synuclein (600 mm ;
in 20 mm phosphate buffer, pH 7.4) was incubated for 50 h at 45 8C
under strong stirring with a Teflon-coated stir bar. The fibrils
formed were diluted to 70 mm with PBS buffer and sonicated for
4 min with a probe sonicator (Bandelin, Solopuls HD 2070) at 10%
maximum power and with 30% cycles.
Thioflavin T kinetic assay: Experiments with ThT were carried out
in an Optima Fluostar platereader (BMG Labtech, Ortenburg, Ger-
Figure 4. Kinetic traces of the change in intrinsic fluorescence intensity (*)
and ThT fluorescence (c) during seeded aggregation of a-synuclein in-
cubated at 37 8C with (red) and without (blue) added lacmoid (100 mm). In
both cases, [fibril seed]=7 mm and [monomeric protein]=70 mm.
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many). Samples were prepared that contained monomeric a-synu-
clein (70 or 35 mm), sonicated seed fibrils (7 or 3.5 mm) and Thiofla-
vin T (100 mm). The experiments with lacmoid were performed by
diluting a stock solution of lacmoid (10 mm) in DMSO 100-fold into
the above solution of ThT, fibrillar, and monomeric a-synuclein.
The control experiment in this case therefore contained 1% (v/v)
DMSO. We used half-area, low-binding, clear-bottom, 96-well
plates (Corning). The experiments were performed under quiescent
conditions so as to simulate as closely as possible the intrinsic fluo-
rescence time-course measurements.
Atomic force microscopy (AFM): AFM images were acquired by
using a VEECO Dimension 3100 atomic force microscope (Bruker)
and a JPK Nanowizard (JPK, Cambridge, UK). The instruments were
operated in tapping mode in air by using silicon cantilevers with
a resonant frequency of 300 kHz, a spring constant of 40 Nm1
and a tip radius of 10 nm (RTESP, Bruker AXS). Images were collect-
ed at a scan rate of 1 Hz. Each fibrillar sample (5 mL) was deposited
onto freshly cleaved mica surfaces for 2 h for adsorption. The sam-
ples were rinsed with Milli-Q water (5200 mL) and left to dry com-
pletely in air before imaging.
Confocal microscopy and spectral imaging: Spatially resolved
images of the intrinsic fluorescence of amyloid fibrils were ob-
tained with a confocal microscope (Leica TCS SP5, Leica Microsys-
tems), with a 405 nm diode laser as the excitation source and a 63-
fold, 1.4 NA oil immersion objective. These experiments were per-
formed on the same samples as imaged by AFM. An emission
bandwidth of 20 nm was used for the spectral measurements. It
was verified that photobleaching was insignificant during image
and spectrum acquisition. In the kinetic experiments, the intrinsic
fluorescence intensity at each time point was integrated over a
defined confocal volume taken at ten different focal (Z) planes.
Fluorescence lifetime imaging microscopy (FLIM): All fluores-
cence lifetime images were recorded on a home-built confocal mi-
croscopy platform based on a confocal microscope scanning unit
(Olympus FluoView 300) coupled with an Olympus IX70 inverted
microscope frame. Details can be found in ref. [13] .
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